Levi Strauss cut its revenue outlook for the year and is once again exploring the potential sale of Dockers, the latest move by CEO Michelle Gass to focus the company on its namesake brand. The ...
The Food and Drug Administration declared an end to the scarcity of Eli Lilly's highly in-demand weight-loss and diabetes ...
A surge of alternatives to newly popular weight-loss drugs is facing its biggest test yet after the FDA warned companies ...
Eli Lilly's weight-loss drug Zepbound and diabetes medication Mounjaro are no longer in short supply. That could limit ...
Ozempic and other diabetes-weight loss drugs have been linked to at least 162 deaths and 10,000 cases involving “serious” ...
The FDA has removed two of Eli Lilly's in-demand weight-loss and diabetes drugs from its shortage list. Diabetes drug ...
The FDA says the shortage of tirzepatide injection — a glucagon-like peptide 1 medication used for diabetes and weight loss — ...
The shortage of Eli Lilly’s (LLY) blockbuster diabetes and weight loss drugs is officially over, according to the U.S. Food ...
Indianapolis-based Eli Lilly’s supply of Mounjaro, which is used to treat Type 2 diabetes, and popular weight-loss drug ...
God knows what volume they’re actually selling. And who knows? You’re just taking it,” one expert told The Post.
The change will expand access to the diabetes and weight-loss drugs. But it will also complicate the future of compounded ...
The drug, called Mounjaro in the UK and Zepbound in the U.S., would be initially offered to obese people with at least three ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback